A novel prostate carcinoma‐associated glycoprotein complex (PAC) recognized by monoclonal antibody turp‐27

Abstract

A prostate carcinoma-associated antigen recognized by MAb TURP-27 was characterized immunohistochemically and biochemically. TURP-27 antigen was found localized in the cell membrane and cytoplasm of the ductal epithelial cells of normal (10%), benign (75-100%) and malignant (20-100%) prostate cells. Fetal prostate tissues were also found to express the TURP-27 antigen, suggesting expression early in development. This antigen was not expressed by non-prostate tumors examined, but significant cross-reactivity was observed in myelinated nerves while minor cross-reactivity was seen in certain lymphocyte subsets, cells in the adrenal medulla and chief cells of stomach. Immunoblotting and biochemical data demonstrated that the TURP-27 antigen is a sialic-acid-containing glycoprotein complex with major molecular species in prostate tissues of 310-250, 180, 140, 115, 95-90, 69, and 40- to 35-kDa. Immunoblotting patterns similar to those observed for prostate tissues were also seen in CNS extracts with the exception of the 69 and 40- to 35-kDa proteins. This prostate carcinoma-associated sialoglycoprotein complex (PAC) recognized by MAb TURP-27 is likely to represent a novel tumor antigen expressed by prostate tumors.

Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancer

“…TURP-27 is a mouse IgG, monoclonal antibody [25] that reacts to the prostatecancer-associated-glycoprotein complex (PAC) [26]. In the normal prostate, TURP-27 is reactive in 100% of cases [26].…”

“…TURP-27 is a mouse IgG, monoclonal antibody [25] that reacts to the prostatecancer-associated-glycoprotein complex (PAC) [26]. In the normal prostate, TURP-27 is reactive in 100% of cases [26]. This reactivity can be demonstrated in embryos as early as the second trimester of gestation [26].…”

“…In the normal prostate, TURP-27 is reactive in 100% of cases [26]. This reactivity can be demonstrated in embryos as early as the second trimester of gestation [26]. However, in both fetal and normal prostates, reactivity is limited to a few scattered cells [25,26].…”

Serum levels of endothelial and neural cell adhesion molecules in prostate cancer

“…Furthermore, VCAM-1 and Eselectin have been reported to mediate adhesion of melanoma cells or colon carcinoma cells to the endothelium [4], and NCAM is expressed by Wilms' tumor, small-cell lung carcinoma (SCLC), and other neuroectodermal malignancies [8,9]. In addition, previous reports from our laboratory have shown that NCAMlike molecules are overexpressed in BPH and CaP [11][12][13]. Soluble variants of endothelial CAMs and NCAM have recently been identified in the circulation and appear to reflect the activity of some epithelial cancers, suggesting that elevated levels may be useful as diagnostic and prognostic markers [7].…”

“…Based on our previous findings that NCAM-like molecules are overexpressed in benign and malignant prostate tissues [11][12][13], it was anticipated that abnormal levels of soluble NCAM might be found in sera from patients with BPH or CaP. However, only slight elevations of NCAM were found in sera from a few CaP patients with androgen-independent tumors.…”